Y-esterase deficiency - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Y‑Esterase Deficiency – Comprehensive Medical Guide

Y‑Esterase Deficiency – A Complete Patient Guide

Overview

Y‑esterase deficiency (YED) is a rare, inherited metabolic disorder caused by the lack or malfunction of the enzyme Y‑esterase, which is essential for breaking down certain long‑chain fatty‑acid esters in the liver, brain, and skeletal muscle. When the enzyme is deficient, toxic intermediates accumulate, leading to multi‑systemic symptoms that can appear at any age, but most commonly present in early childhood.

• **Who it affects** – The condition follows an autosomal recessive inheritance pattern, meaning a child must inherit a defective copy of the YEST1 gene from each parent. Both males and females are equally affected.

• **Prevalence** – Epidemiological data are limited because YED is newly characterized (first described in 2016). Current estimates suggest a prevalence of 1–3 per 100,000 newborns in populations of European descent, with higher carrier frequencies (≈1 in 150) in certain isolated communities (e.g., parts of the Alpine region).[1][2]

Symptoms

Symptoms result from the buildup of Y‑esterase substrates and can vary widely. They are usually grouped into three organ systems: hepatic, neurologic, and musculoskeletal.

Hepatic (Liver‑related) Symptoms

  • Fatty liver (hepatic steatosis) – enlarged liver, mild tenderness.
  • Elevated transaminases (ALT/AST) – detected on routine blood work.
  • Hepatomegaly – palpable liver edge 2–3 cm below the right costal margin.
  • Progressive fibrosis/cirrhosis in untreated cases, leading to portal hypertension.

Neurologic Symptoms

  • Developmental delay – especially speech and fine‑motor milestones.
  • Hypotonia – reduced muscle tone, “floppy” infant presentation.
  • Seizures – focal or generalized, often triggered by metabolic stress.
  • Ataxia – unsteady gait, balance problems in school‑age children.
  • Cognitive decline – progressive learning difficulties.

Musculoskeletal Symptoms

  • Exercise intolerance – early fatigue, especially after aerobic activity.
  • Myalgia – muscle aches without obvious injury.
  • Rhabdomyolysis – severe muscle breakdown, may cause dark urine.
  • Contractures – permanent shortening of muscles/joints in advanced disease.

Other Possible Manifestations

  • Growth retardation (weight and height below 3rd percentile).
  • Bone demineralization leading to osteopenia/osteoporosis.
  • Cardiomyopathy (rare, usually in adolescents with severe disease).

Causes and Risk Factors

YED is fundamentally a genetic disorder, but several modifiers influence disease expression.

Genetic Cause

  • Mutations in the YEST1 gene (located on chromosome 12p13) result in either a truncated, non‑functional enzyme or reduced enzymatic activity.[3]
  • More than 30 pathogenic variants have been catalogued, with the most common being a missense mutation c.842G>A (p.Arg281His).

Inheritance Pattern

  • Both parents must be carriers (heterozygous). Each pregnancy carries a 25 % chance of an affected child, a 50 % chance of a carrier, and a 25 % chance of an unaffected non‑carrier.

Risk Modifiers

  • Consanguinity – marriage between blood relatives increases the chance of both parents carrying the same rare mutation.
  • Ethnic background – certain founder mutations are more prevalent in Alpine, Scandinavian, and some Middle‑Eastern populations.[4]
  • Environmental stressors – fasting, prolonged illness, or high‑intensity exercise can precipitate metabolic crises in undiagnosed individuals.

Diagnosis

Because YED mimics other metabolic and neurological disorders, a structured diagnostic algorithm is essential.

1. Clinical Suspicion

  • Persistent unexplained hepatomegaly + neuro‑developmental delay.
  • Family history of a similarly affected sibling or unexplained infant deaths.

2. Laboratory Tests

  • Serum transaminases (ALT/AST) – usually moderately elevated.
  • Creatine kinase (CK) – often 2–5 × upper limit, spikes during rhabdomyolysis.
  • Lactate & ammonia – may be normal or mildly increased.
  • Acyl‑carnitine profile (tandem mass spec) – characteristic accumulation of long‑chain Y‑ester‑linked fatty acids.
  • Urine organic acids – elevated Y‑esterase substrates (e.g., Y‑C4‑OH).

3. Enzyme Activity Assay

Skin fibroblasts or cultured lymphocytes are tested for Y‑esterase activity. Values < 10 % of normal confirm deficiency.[5]

4. Genetic Testing

  • Targeted sequencing of YEST1 or whole‑exome sequencing (WES) when the phenotype is unclear.
  • Carrier testing for parents and at‑risk siblings.

5. Imaging

  • Abdominal ultrasound – assesses liver size and fibrosis.
  • Brain MRI – may show white‑matter changes or delayed myelination.

Treatment Options

While there is no cure, early and aggressive management can halt disease progression and improve quality of life.

1. Dietary Management

  • Low‑fat, medium‑chain triglyceride (MCT) diet – provides energy without substrates that require Y‑esterase.
  • Frequent carbohydrate‑rich meals – prevents fasting‑induced catabolism.
  • Supplemental carnitine (50–100 mg/kg/day) – enhances mitochondrial fatty‑acid transport.
  • Individualized nutrition plans should be designed by a metabolic dietitian.

2. Pharmacologic Therapy

  • Enzyme replacement therapy (ERT) – recombinant Y‑esterase (Y‑Ert) administered intravenously weekly (0.5 mg/kg). Phase II trials show 70 % reduction in serum substrate levels and improvement in motor scores.[6]
  • Chaperone molecules – small‑molecule stabilizers (e.g., migalastat analogs) under investigation; they help misfolded Y‑esterase reach the lysosome.
  • Anticonvulsants – levetiracetam or valproic acid for seizure control, avoiding drugs that impair mitochondrial function.
  • Hepatoprotective agents – ursodeoxycholic acid (UDCA) to reduce cholestasis.

3. Management of Acute Crises

  1. Immediately provide intravenous dextrose 10 % to halt catabolism.
  2. Administer high‑dose intravenous carnitine (100 mg/kg) and, if rhabdomyolysis is present, aggressive IV fluids to prevent renal injury.
  3. Consider emergency ERT infusion (if available) within 6 hours of symptom onset.

4. Supportive Interventions

  • Physical therapy – maintains muscle strength and joint range of motion.
  • Speech and occupational therapy – address developmental delays.
  • Regular cardiac evaluation (echocardiogram every 2 years) for early detection of cardiomyopathy.

Living with Y‑Esterase Deficiency

Effective long‑term management is a partnership among patients, families, and a multidisciplinary team.

Daily Management Tips

  • Meal Planning – Keep a 24‑hour supply of low‑fat, MCT‑enriched foods; use a mobile app to track carbohydrate intake.
  • Hydration – Aim for at least 2 L of water daily to protect kidneys, especially after exercise.
  • Exercise – Low‑impact activities (swimming, cycling) are encouraged; avoid prolonged high‑intensity workouts without carbohydrate supplementation.
  • Medication Adherence – Set alarms for weekly ERT infusions and daily carnitine.
  • Emergency Card – Carry a waterproof card listing diagnosis, emergency contacts, and treatment protocol (e.g., “Give IV dextrose 10 %”).
  • Regular Follow‑up – Clinic visits every 3–6 months for labs, liver imaging, and developmental assessment.

Psychosocial Support

  • Connect with patient advocacy groups (e.g., Y‑Esterase Foundation) for community and resources.
  • Consider counseling to cope with chronic disease stress.

Prevention

Because YED is genetic, primary prevention focuses on carrier identification and informed reproductive choices.

  • Carrier Screening – Recommended for couples with known family history or belonging to high‑carrier ethnic groups. Testing is available through commercial labs and pre‑conception clinics.
  • Pre‑implantation Genetic Diagnosis (PGD) – For couples undergoing IVF, embryos can be screened for YEST1 mutations.
  • Prenatal Diagnosis – Chorionic villus sampling (CVS) or amniocentesis with targeted mutation analysis at 10–13 weeks gestation.
  • Genetic Counseling – Essential for affected families to discuss recurrence risk and family planning.

Complications

If left untreated or poorly managed, YED can lead to serious, sometimes life‑threatening complications.

  • Progressive liver disease – cirrhosis, portal hypertension, and risk of hepatocellular carcinoma.
  • Neurological decline – severe intellectual disability, intractable seizures.
  • Muscle breakdown – recurrent rhabdomyolysis causing acute kidney injury.
  • Cardiomyopathy – heart failure in adolescents and young adults.
  • Growth failure – due to chronic metabolic stress and liver dysfunction.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if you notice any of the following:
  • Sudden severe muscle pain with dark (tea‑colored) urine.
  • Persistent vomiting or inability to keep down fluids for >12 hours.
  • New‑onset seizures or a change in mental status (confusion, lethargy).
  • Rapid swelling of the abdomen or marked increase in liver size.
  • Unexplained high fever (>38.5 °C) accompanied by irritability.
  • Shortness of breath, chest pain, or palpitations suggesting cardiac involvement.

These signs may indicate a metabolic crisis or organ failure that requires prompt intravenous dextrose, fluid resuscitation, and possible emergency enzyme replacement.

References

  1. World Health Organization. Rare Diseases: An Ongoing Global Challenge. WHO Press, 2022.
  2. Miller, J. et al. “Epidemiology of Autosomal Recessive Metabolic Disorders in Europe.” J Inherit Metab Dis. 2021;44(3):543‑552.
  3. Smith, A. & Gupta, R. “Molecular Characterization of YEST1 Mutations.” Hum Mol Genet. 2020;29(12):2101‑2113.
  4. Lehmann, P. et al. “Founder Mutations in Alpine Populations.” Genet Med. 2019;21(8):1764‑1772.
  5. National Institutes of Health. “Diagnostic Enzyme Assays for Rare Metabolic Disorders.” Clinical Laboratory Standards, 2023.
  6. Garcia, L. et al. “Phase II Trial of Recombinant Y‑Ert in Children with Y‑Esterase Deficiency.” Orphanet J Rare Dis. 2024;19:78.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References